Multiple studies have shown superior survival benefits for anti‐PD‐1/PD‐L1 inhibitors plus chemotherapy compared to chemotherapy in NSCLC patients without EGFR or ALK alterations.8, 9, 10, 11. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.